Assessing neuroprotective effects of diroximel fumarate and siponimod via modulation of pacemaker channels in an experimental model of remyelination.

Cuprizone (CPZ)-induced alterations in axonal myelination are associated with a period of neuronal hyperexcitability and increased activity of hyperpolarization-activated and cyclic nucleotide-gated (HCN) channels in the thalamocortical (TC) system. Substances used for the treatment of multiple sclerosis (MS) have been shown to normalize neuronal excitability in CPZ-treated mice. Therefore, we aimed to examine the effects of diroximel fumarate (DRF) and the sphingosine 1-phospate receptor (S1PR) modulator siponimod on action potential firing and the inward current (I h) carried by HCN ion channels in naive conditions and during different stages of de- and remyelination. Here, DRF application reduced I h current density in ex vivo patch clamp recordings from TC neurons of the ventrobasal thalamic complex (VB), thereby counteracting the increase of I h during early remyelination. Siponimod reduced I h in VB neurons under control conditions but had no effect in neurons of the auditory cortex (AU). Furthermore, siponimod increased and decreased AP firing properties of neurons in VB and AU, respectively. Computational modeling revealed that both DRF and siponimod influenced thalamic bursting during early remyelination by delaying the onset and decreasing the interburst frequency. Thus, substances used in MS treatment normalize excitability in the TC system by influencing AP firing and I h. • Axonal de- and remyelination influence neuronal excitability and Ih currents. • The cuprizone model is a powerful tool to study the myelination process in vitro. • Drugs used in MS therapy normalize hyperexcitability in distinct brain regions. • Diroximel fumarate (DRF) impacts thalamic bursting only during early remyelination. • Siponimod acts opposingly on thalamic and cortical neurons in all conditions. [ABSTRACT FROM AUTHOR]